(+-)-ByakangelicinCAS# 19573-01-4 |
- Byakangelicin
Catalog No.:BCN9028
CAS No.:482-25-7
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 19573-01-4 | SDF | Download SDF |
| PubChem ID | 10211 | Appearance | Powder |
| Formula | C17H18O7 | M.Wt | 334.32 |
| Type of Compound | Coumarins | Storage | Desiccate at -20°C |
| Synonyms | Byakangelicin; Bjakangelicin; Byankagelicine; Bjacangelicin; Biacangelicin; Byak-Angelicin;482-25-7 | ||
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | 9-[(2R)-2,3-dihydroxy-3-methylbutoxy]-4-methoxyfuro[3,2-g]chromen-7-one | ||
| SMILES | CC(C)(C(COC1=C2C(=C(C3=C1OC(=O)C=C3)OC)C=CO2)O)O | ||
| Standard InChIKey | PKRPFNXROFUNDE-LLVKDONJSA-N | ||
| Standard InChI | InChI=1S/C17H18O7/c1-17(2,20)11(18)8-23-16-14-10(6-7-22-14)13(21-3)9-4-5-12(19)24-15(9)16/h4-7,11,18,20H,8H2,1-3H3/t11-/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Byakangelicin is found in extracts of the root of Angelica dahurica, used in Korea and China as a traditional medicine to treat colds, headache and toothache, it can inhibit the effects of sex hormones, it may increase the catabolism of endogenous hormones, it induces cytochrome P450 3A4 expression via transactivation of pregnane X receptors in human hepatocytes. Byakangelicin is effective for the treatment of sugar cataracts and diabetic neuropathy in rats. Byakangelicin could as insecticides and insect antifeedant for the control of Lepidoptera and Homoptera showed a significant effect. |
| Targets | P450 (e.g. CYP17) | Sodium Channel | ATPase | Potassium Channel |
| In vitro | Application of byakangelicin used as agricultural insect antifeedant and pesticide.[Reference: WebLink]CN 103109822 A[P]. 2013.The invention discloses an application of Byakangelicin used as an agricultural pesticide and an insect antifeedant. The Byakangelicin has an obvious effect of preventing and controlling lepidopterous insects and homoptera when being used as the pesticide and the insect antifeedant, and also has the characteristics of low toxicity without any residues or pollutions when being used as the agricultural pesticide, so that environmental protection is favored. |
| In vivo | Effect of byakangelicin, an aldose reductase inhibitor, on galactosemic cataracts, the polyol contents and Na(+), K(+)ATPase activity in sciatic nerves of strepto-zotocin-induced diabetic rats.[Pubmed: 23195764]Phytomedicine. 1998 Apr;5(2):121-7.Byakangelicin, a main furanocoumarin constituent isolated and characterized as an aldose reductase inhibitor from the roots of Angelica dahurica, was evaluated for usefulness in the treatment of galactosemic cataract and diabetic complications in animal experiments.
|
| Cell Research | Byakangelicin induces cytochrome P450 3A4 expression via transactivation of pregnane X receptors in human hepatocytes.[Pubmed: 20942813]Br J Pharmacol. 2011 Jan;162(2):441-51.Byakangelicin is found in extracts of the root of Angelica dahurica, used in Korea and China as a traditional medicine to treat colds, headache and toothache. As Byakangelicin can inhibit the effects of sex hormones, it may increase the catabolism of endogenous hormones. Therefore, this study investigated the effects of Byakangelicin on the cytochrome P450 isoform cytochrome (CY) P3A4 in human hepatocytes.
|
| Animal Research | Endocrinological studies on plant products: part 5. Effect of byakangelicin on female sex hormones and on fertility of rats.[Reference: WebLink]Indian J. Exp. Biology, 1967, 5(2):75-9.The effect of Byakangelicin on female sex hormones and on fertility of rats and rabbits was investigated. Intact and castrate albino rats received sc injections of 1-3 mg/day/rat for 6 days 3 days alone and 3 days with 5 IU estradiol. Immature rabbits received im injections of 50 IU of estrogen for 3 days followed by 3-6 mg of Byakangelicin/day along with the same amount of hormone for 3 more days. The animals were sacrificed 24 hours after the last injection. Changes in gross uterine weight histological and histochemical examinations of tissues and vaginal smear test indicated that Byakangelicin partially blocked the uterotropic respones of exogenous estrogen. No effect on the progesterone response of the uterus was seen. Byakangelicin caused irregularity of estrous cycle delay in mating and a marked decrease in fertile mating and in number of offspring. It appeared that Byakangelicin might delay the sexual maturity of rats. |
| Structure Identification | Arch Pharm Res. 2003 Aug;26(8):606-11.Identification of new urinary metabolites of byakangelicin, a component of Angelicae dahuricae Radix, in rats.[Pubmed: 12967195]Byakangelicin, 9-(2,3-dihydroxy-2-methylbutoxy)-4-methoxy-7H-furo[3,2-g][l]benzopyran-7-one (BKG), a component of Angelicae dahuricae Radix, is considered to be an inhibitor of aldose reductase for the treatment of diabetic cataract.
|
(+-)-Byakangelicin Dilution Calculator
(+-)-Byakangelicin Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.9911 mL | 14.9557 mL | 29.9115 mL | 59.8229 mL | 74.7787 mL |
| 5 mM | 0.5982 mL | 2.9911 mL | 5.9823 mL | 11.9646 mL | 14.9557 mL |
| 10 mM | 0.2991 mL | 1.4956 mL | 2.9911 mL | 5.9823 mL | 7.4779 mL |
| 50 mM | 0.0598 mL | 0.2991 mL | 0.5982 mL | 1.1965 mL | 1.4956 mL |
| 100 mM | 0.0299 mL | 0.1496 mL | 0.2991 mL | 0.5982 mL | 0.7478 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 2,16,19-Kauranetriol 2-O-beta-D-allopyranoside
Catalog No.:BCN1510
CAS No.:195723-38-7
- Methyl 4-O-feruloylquinate
Catalog No.:BCC9041
CAS No.:195723-10-5
- Piromidic Acid
Catalog No.:BCC3840
CAS No.:19562-30-2
- AP1903
Catalog No.:BCC5361
CAS No.:195514-63-7
- Chiirirhamnin
Catalog No.:BCN3179
CAS No.:195450-50-1
- Wortmannin
Catalog No.:BCC3874
CAS No.:19545-26-7
- Bay 11-7821(BAY 11-7082)
Catalog No.:BCC2244
CAS No.:19542-67-7
- JAK2 Inhibitor V, Z3
Catalog No.:BCC1667
CAS No.:195371-52-9
- Alphitolic acid
Catalog No.:BCN1189
CAS No.:19533-92-7
- Galantamine hydrobromide
Catalog No.:BCN2869
CAS No.:1953-04-4
- Tiopronin (Thiola)
Catalog No.:BCC3870
CAS No.:1953-02-2
- GLP-2 (rat)
Catalog No.:BCC5892
CAS No.:195262-56-7
- Atrasentan hydrochloride
Catalog No.:BCC1380
CAS No.:195733-43-8
- 2,6,16-Kauranetriol 2-O-beta-D-allopyranoside
Catalog No.:BCN1509
CAS No.:195735-16-1
- HTMT dimaleate
Catalog No.:BCC6736
CAS No.:195867-54-0
- (R)-Nepicastat HCl
Catalog No.:BCC4315
CAS No.:195881-94-8
- 25S-Inokosterone
Catalog No.:BCN3873
CAS No.:19595-18-7
- 17 alpha-propionate
Catalog No.:BCC1296
CAS No.:19608-29-8
- Angelol A
Catalog No.:BCN8036
CAS No.:19625-17-3
- Indole-3-acrylic acid methyl ester
Catalog No.:BCN1190
CAS No.:19626-92-7
- 4-Methoxycinnamaldehyde
Catalog No.:BCN2700
CAS No.:1963-36-6
- Bay 11-7085
Catalog No.:BCC5105
CAS No.:196309-76-9
- Axillarine
Catalog No.:BCN2059
CAS No.:19637-66-2
- Prosaptide TX14(A)
Catalog No.:BCC8020
CAS No.:196391-82-9
Effect of byakangelicin, an aldose reductase inhibitor, on galactosemic cataracts, the polyol contents and Na(+), K(+)ATPase activity in sciatic nerves of strepto-zotocin-induced diabetic rats.[Pubmed:23195764]
Phytomedicine. 1998 Apr;5(2):121-7.
Byakangelicin, a main furanocoumarin constituent isolated and characterized as an aldose reductase inhibitor from the roots of Angelica dahurica, was evaluated for usefulness in the treatment of galactosemic cataract and diabetic complications in animal experiments. Cataract formation and galactitol accumulation in the lenses of rats fed a 30% galactose diet were significantly prevented by intragastric (i.g.) administration of byakangelicin at a dose of 100 mg/kg for 14 days. Administration of the drug for 18 days was found to suppress sorbitol accumulation and cause a significant reversal of depleted myo-inositol contents as well as Na(+),K(+)ATPase activity in the sciatic nerves of streptozotocin-induced diabetic rats. These results indicate that in rats, byakangelicin is effective for the treatment of sugar cataracts and diabetic neuropathy and hence might be useful as a lead compound for the development of new type drugs for clinical use.
Identification of new urinary metabolites of byakangelicin, a component of Angelicae dahuricae Radix, in rats.[Pubmed:12967195]
Arch Pharm Res. 2003 Aug;26(8):606-11.
Byakangelicin, 9-(2,3-dihydroxy-2-methylbutoxy)-4-methoxy-7H-furo[3,2-g][l]benzopyran-7-one (BKG), a component of Angelicae dahuricae Radix, is considered to be an inhibitor of aldose reductase for the treatment of diabetic cataract. An analytical method for the isolation of BKG developed by high-performance liquid chromatography has been reported. No literature on the metabolism of BKG, however, has been found. With the purpose of identifying new metabolites of BKG, BKG (100 mg/kg) was orally administered to Sprague-Dawley rats via a gavage. Using a metabolic cage, urine was collected for 24 h, and the urine samples were extracted by liquid-liquid extraction. For structural identification of new urinary metabolites of BKG, various instrumental analyses were conducted by gas-chromatography/mass spectrometry, high-performance liquid chromatography/diode array detector, liquid chromatography/mass spectroscopy with thermospray interface and 1H nuclear magnetic resonance spectroscopy. Two metabolites produced from the O-demethylation or O-dealkylation of BKG were newly identified, and another new but unknown metabolite was assumed to be the hydroxylated form of BKG. These results indicate that the major metabolic products of BKG are formed by O-demethylation or O-dealkylation of BKG side chains.
Byakangelicin induces cytochrome P450 3A4 expression via transactivation of pregnane X receptors in human hepatocytes.[Pubmed:20942813]
Br J Pharmacol. 2011 Jan;162(2):441-51.
BACKGROUND AND PURPOSE: Byakangelicin is found in extracts of the root of Angelica dahurica, used in Korea and China as a traditional medicine to treat colds, headache and toothache. As byakangelicin can inhibit the effects of sex hormones, it may increase the catabolism of endogenous hormones. Therefore, this study investigated the effects of byakangelicin on the cytochrome P450 isoform cytochrome (CY) P3A4 in human hepatocytes. EXPERIMENTAL APPROACH: Cultures of human hepatocytes and a hepatoma cell line (Huh7 cells) were used. mRNA and protein levels were measured by quantitative reverse transcription-polymerase chain reaction and Western blot. Plasmid constructs and mutants were prepared by cloning and site-directed mutagenesis. Reporter (luciferase) activity was determined by transient co-transfection experiments. KEY RESULTS: In human primary hepatocytes, byakangelicin markedly induced the expression of CYP3A4 both at the mRNA level (approximately fivefold) and the protein level (approximately threefold) but did not affect expression of human pregnane X receptor (hPXR). In reporter assays, byakangelicin activated CYP3A4 promoter in a concentration-dependent manner (EC(5)(0) = 5 microM), and this activation was enhanced by co-transfection with hPXR. Further reporter assays demonstrated that the eNR4 binding element in the CYP3A4 promoter was required for the transcriptional activation of CYP3A4 by byakangelicin. CONCLUSIONS AND IMPLICATIONS: Byakangelicin induced expression and activity of CYP3A4 in human hepatocytes. This induction was achieved by the transactivation of PXR and not by increased expression of PXR. Therefore, byakangelicin is likely to increase the expression of all PXR target genes (such as MDR1) and induce a wide range of drug-drug interactions.
